Alexza Pharmaceuticals, Inc. To Release First Quarter Results On May 15, 2006

PALO ALTO, Calif., May 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that it will release results for the first quarter of 2006 on Monday May 15, 2006, at 4:15 p.m. Eastern Time. The company will host a conference call at 4:30 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event. The conference call, replay and webcast are open to all interested parties.

To access the conference call via the Internet, go to http://www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required.

To access the live conference call via phone, dial 1-800-299-0148. International callers may access the live call by dialing 1-617-801-9711. The reference number to enter the call is 65230502.

The replay of the conference call may be accessed via the Internet, at http://www.alexza.com, or via phone at 1-888-286-8010 for domestic callers or 1-617-801-6888 for international callers. The reference number to enter the replay of the call is 32562043.

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(TM) system, vaporizes unformulated drug compound to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has four product candidates in clinical development; AZ-001 (Staccato prochlorperazine) for the treatment of acute migraine headaches, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia and AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain.

Alexza Pharmaceuticals

CONTACT: Thomas B. King, President & CEO of Alexza Pharmaceuticals,+1-650-687-3900 or tking@alexza.com

Back to news